Literature DB >> 34617185

Effect of Dapagliflozin on the Functioning of Rat Liver Mitochondria In Vitro.

N V Belosludtseva1, V S Starinets1, K N Belosludtsev2.   

Abstract

We studied the effect of a new hypoglycemic compound dapagliflozin on the functioning of rat liver mitochondria. Dapagliflozin in concentrations of 10-20 μM had no effect on the parameters of respiration and oxidative phosphorylation of rat liver mitochondria. Increasing dapagliflozin concentration to 50 μM led to a significant inhibition of mitochondrial respiration in states 3 and 3UDNP. Dapagliflozin in this concentration significantly reduced calcium retention capacity of rat liver mitochondria. These findings indicate a decline in the resistance of rat liver mitochondria to induction of Ca2+-dependent mitochondrial permeability transition pore. In a concentration of 10 μM, dapagliflozin significantly decreases the rate of H2O2 formation in rat liver mitochondria, which attested to an antioxidant effect of this compound. Possible mitochondrion-related mechanisms of the protective action of dapagliflozin on liver cells are discussed.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  dapagliflozin; mitochondria; mitochondrial permeability transition pore; mitochondrial respiration; reactive oxygen species

Mesh:

Substances:

Year:  2021        PMID: 34617185      PMCID: PMC8494602          DOI: 10.1007/s10517-021-05277-2

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  14 in total

Review 1.  Mitochondrial Ca2+ Transport: Mechanisms, Molecular Structures, and Role in Cells.

Authors:  K N Belosludtsev; M V Dubinin; N V Belosludtseva; G D Mironova
Journal:  Biochemistry (Mosc)       Date:  2019-06       Impact factor: 2.487

2.  Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts.

Authors:  Tsung-Ming Lee; Nen-Chung Chang; Shinn-Zong Lin
Journal:  Free Radic Biol Med       Date:  2017-01-26       Impact factor: 7.376

3.  Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin.

Authors:  Rao N V S Mamidi; Jim Proctor; Sandra De Jonghe; Bianca Feyen; Esther Moesen; Petra Vinken; Jing Ying Ma; Stewart Bryant; Sandra Snook; Calvert Louden; Godelieve Lammens; Kirk Ways; Michael F Kelley; Mark D Johnson
Journal:  Chem Biol Interact       Date:  2014-08-14       Impact factor: 5.192

Review 4.  Epidemiology of diabetes.

Authors:  Nathaniel Winer; James R Sowers
Journal:  J Clin Pharmacol       Date:  2004-04       Impact factor: 3.126

Review 5.  Medication-Induced Nephrotoxicity in Older Patients.

Authors:  Sergio Fusco; Sabrina Garasto; Andrea Corsonello; Silvio Vena; Vincenzo Mari; Pietro Gareri; Giovanni Ruotolo; Filippo Luciani; Arturo Roncone; Marcello Maggio; Fabrizia Lattanzio
Journal:  Curr Drug Metab       Date:  2016       Impact factor: 3.731

Review 6.  The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies.

Authors:  Melanie Davies; Sudesna Chatterjee; Kamlesh Khunti
Journal:  Clin Pharmacol       Date:  2016-06-23

7.  Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission.

Authors:  Hao Zhou; Shuyi Wang; Pingjun Zhu; Shunying Hu; Yundai Chen; Jun Ren
Journal:  Redox Biol       Date:  2017-12-30       Impact factor: 11.799

8.  Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect.

Authors:  Philipp F Secker; Sascha Beneke; Nadja Schlichenmaier; Johannes Delp; Simon Gutbier; Marcel Leist; Daniel R Dietrich
Journal:  Cell Death Dis       Date:  2018-02-14       Impact factor: 8.469

9.  Transport of Ca2+ and Ca2+-Dependent Permeability Transition in Rat Liver Mitochondria under the Streptozotocin-Induced Type I Diabetes.

Authors:  Konstantin N Belosludtsev; Eugeny Yu Talanov; Vlada S Starinets; Alexey V Agafonov; Mikhail V Dubinin; Natalia V Belosludtseva
Journal:  Cells       Date:  2019-08-30       Impact factor: 6.600

Review 10.  SARS-CoV-2 and diabetes: New challenges for the disease.

Authors:  Cecília Cristelo; Cláudia Azevedo; Joana Moreira Marques; Rute Nunes; Bruno Sarmento
Journal:  Diabetes Res Clin Pract       Date:  2020-05-22       Impact factor: 5.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.